0.5108

27.19% 0.1092

After Hours: .48 -0.0308 -6.03%

Neurosense Therapeutics Ltd (NRSN)

Overview News Price History Discussions Forecast

Neurosense Therapeutics Ltd stock is traded at $0.5108, with a volume of 4.14M. It is up +27.19% in the last 24 hours and down -1.75% over the past month. NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Previous Close:

$0.4016

Open:

$0.4

24h Volume:

4.14M

Relative Volume:

14.54

Market Cap:

$19.29M

Revenue:

Net Income/Loss:

$-10.21M

P/E Ratio:

-0.8744

EPS:

-0.5842

Net Cash Flow:

1W Performance:

+21.50%

1M Performance:

-1.75%

6M Performance:

-42.54%

1Y Performance:

-53.56%

1-Day Range:

$0.36

$0.5257

1-Week Range:

$0.36

$0.5257

52-Week Range:

$0.25

$1.98

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Name

Neurosense Therapeutics Ltd

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-06-30

Latest SEC Filings

NRSN's Discussions on Twitter

Compare NRSN vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRSN Neurosense Therapeutics Ltd	0.5108	13.23M	0	-10.21M	0	-0.5842
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Neurosense Therapeutics Ltd Stock (NRSN) Latest News

07:05 AM

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS - morningstar.com

Aug 31, 2026

NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval - TipRanks

Aug 31, 2026

Aug 27, 2026

NeuroSense Therapeutics Ltd. Warrant (NRSNW) Peer Comparison – Compare with Others - Value Research

Aug 27, 2026

Aug 25, 2026

NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSN - TradingView

Aug 25, 2026

12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm

Aug 25, 2026

Aug 23, 2026

NeuroSense (NRSN) Snapshot: Finishes 7.39% Higher at $0.38 in the Latest Reading; Next Session - vinanet.vn

Aug 23, 2026

Aug 14, 2026

Neurosense Therapeutics Stock Price Forecast. Should You Buy NRSN? - StockInvest.us

Aug 14, 2026

NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts - The Globe and Mail

Aug 14, 2026

Aug 13, 2026

Amyotrophic Lateral Sclerosis Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight - openPR.com

Aug 13, 2026

NeuroSense Issues CEO Letter to Shareholders - Nasdaq

Aug 13, 2026

Aug 12, 2026

NeuroSense Therapeutics (NRSN) Slips to $0.47 as Bulls Defend Key Support FloorNHNL Ratio - dars.gov.et

Aug 12, 2026

Aug 11, 2026

Global Neurodegenerative Disease Market is Expected to - GlobeNewswire

Aug 11, 2026

Aug 10, 2026

NeuroSense Therapeutics (NRSN) Dips 1.6% to $0.49, Testing Key Support at $0.47PCR Moving Average - dars.gov.et

Aug 10, 2026

Aug 06, 2026

NeuroSense Advances PrimeC Toward December 2026 Health Canada Filing After Completing Pre-NDS Process - TipRanks

Aug 06, 2026

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - GuruFocus

Aug 06, 2026

Health Canada review path for PrimeC: NeuroSense (NASDAQ: NRSN) - Stock Titan

Aug 06, 2026

Aug 04, 2026

NeuroSense Therapeutics (NRSN) Jumps 11.35% to $0.52, Nears Key Resistance at $0.55Weekly Profile - dars.gov.et

Aug 04, 2026

Aug 03, 2026

CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com

Aug 03, 2026

NeuroSense Therapeutics Ltd. SEC Filing (Aug 3, 2026) - Stock Titan

Aug 03, 2026

Jul 31, 2026

NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split - TipRanks

Jul 31, 2026

NeuroSense Therapeutics (NRSN) seeks reverse split amid Nasdaq compliance push - Stock Titan

Jul 31, 2026

NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective - TipRanks

Jul 31, 2026

Jul 30, 2026

NeuroSense Therapeutics (NRSN) sets $150M shelf and $3.8M ATM share plan - Stock Titan

Jul 30, 2026

Jul 29, 2026

NeuroSense Therapeutics (NRSN) Plunges 14% – Testing Critical Support at $0.46Sentiment Shift - vinanet.vn

Jul 29, 2026

Jul 28, 2026

Neurosense Therapeutics is a buy, this analyst says - Cantech Letter

Jul 28, 2026

Neurosense Therapeutics Ltd expected to post breakeven results a shareEarnings Preview - TradingView

Jul 28, 2026

Jul 27, 2026

Neurosense Therapeutics Ltd. Revenue Breakdown – FWB:H1Z - TradingView

Jul 27, 2026

Neurosense Therapeutics Ltd - TradingKey

Jul 27, 2026